Phosphodiesterase Inhibitor
Sildenafil Citrate 10 mg / 12.5 mL
Intravenous Injection Single Use
Vial 12.5 mL , Each
Auromedics 55150016613

Phosphodiesterase Inhibitor <br>Sildenafil Citrate 10 mg / 12.5 mL <br>Intravenous Injection Single Use <br>Vial 12.5 mL , Each <br> Auromedics  55150016613
Phosphodiesterase Inhibitor
Sildenafil Citrate 10 mg / 12.5 mL
Intravenous Injection Single Use
Vial 12.5 mL , Each
Auromedics 55150016613
Item# Auromedics-55150016613
Regular price: $250.00
Sale price: $226.99
Strength:  Quantity&Size: 

Product Description

Phosphodiesterase Inhibitor <br>Sildenafil Citrate 10 mg / 12.5 mL <br>Intravenous Injection Single Use <br>Vial 12.5 mL , Each <br> Auromedics  55150016613
Phosphodiesterase Inhibitor
Sildenafil Citrate 10 mg / 12.5 mL
Intravenous Injection Single Use
Vial 12.5 mL , Each
Auromedics 55150016613

TERMS & CONDITIONS FOR PURCHASING INJECTABLES & MEDICATIONS : 1- REGULATIONS ON PURCHASE OF INJECTABLES & MEDICATIONS VARY FROM STATE TO STATE . IT IS THE PURCHASER'S RESPONSIBILITY TO KNOW AND COMPLY WITH THE LAWS GOVERNING THE DISTRICT IN WHICH THEY LIVE. 2- INJECTABLES & MEDICATIONS WOULD BE SOLD ONLY TO QUALIFIED CUSTOMERS ( PHYSICIAN OFFICES , DIAGNOSTIC & RESEARCH LABORATORIES , DENTAL OFFICES , HEALTH CARE PROVIDERS , .... ) WITH VALID MEDICAL LICENSE. 3- ORDERS INCLUDING PURCHSE OF INJECTABLES & MEDICATIONS WOULD BE PROCESSED AFTER VERIFICATION OF PURCHASER'S VALID MEDICAL LICENSE TO BE EMAILED AS AN ATTACHMENT TO : ADMIN@ALLMEDTECH.COM OR FAXED TO 323-782-0985 )

Manufacturer # 55150016613 Manufacturer Auromedics Pharmaceuticals Application Phosphodiesterase Inhibitor Container Type Single Use Vial Dosage Form Injection Generic Drug Code 28273 Generic Drug Name Sildenafil Citrate NDC Number 55150-0166-13 Storage Requirements USP Controlled Room Temperature Strength 10 mg / 12.5 mL Type Intravenous UNSPSC Code 51413207 Volume 12.5 mL Features

Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening